These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 11315840

  • 21. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
    Jennings PE, Belch JJ.
    Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
    [Abstract] [Full Text] [Related]

  • 22. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC, Lin CC, Wang TY, Chang MP, Sung FC, Chen CC.
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [Abstract] [Full Text] [Related]

  • 23. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
    Rupprecht E, König E, Limmer J.
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
    [No Abstract] [Full Text] [Related]

  • 24. Cardiovascular effects of conventional sulfonylureas and glimepiride.
    Geisen K, Végh A, Krause E, Papp JG.
    Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD, Balfour JA.
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
    Holstein A, Plaschke A, Hammer C, Egberts EH.
    Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302
    [Abstract] [Full Text] [Related]

  • 29. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
    Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, Gruber D, Harris S, Burger W.
    Eur Heart J; 1999 Mar; 20(6):439-46. PubMed ID: 10213347
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Clinical efficacy of glimepiride].
    Kaneko T, Sakamoto N.
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract] [Full Text] [Related]

  • 32. Vascular function of the peripheral circulation in patients with nephrosis.
    Watts GF, Herrmann S, Dogra GK, Playford DA, Best JD, Thomas MA, Irish A.
    Kidney Int; 2001 Jul; 60(1):182-9. PubMed ID: 11422750
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [Abstract] [Full Text] [Related]

  • 35. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Huang HK, Yeh JI.
    Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
    De Mattia G, Laurenti O, Fava D.
    J Diabetes Complications; 2003 Jun; 17(2 Suppl):30-5. PubMed ID: 12623166
    [Abstract] [Full Text] [Related]

  • 39. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G, Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group, Italian Diabetes Society.
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [Abstract] [Full Text] [Related]

  • 40. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
    Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, Marchionni N, Mannucci E.
    Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.